- August 1, 2024– Webcast to be Held at 8:00 am ET on August 8, 2024 – NEW YORK, August 1, 2024 – Immunic,…
- July 24, 2024– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served…
- July 9, 2024– Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current…
- May 28, 2024NEW YORK, May 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- May 8, 2024– Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the…
- May 6, 2024NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- May 1, 2024– Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK, May 1, 2024 – Immunic,…
- April 30, 2024– 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74%…
- April 4, 2024NEW YORK, April 4, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- March 20, 2024– Patent Will Also Cover a Related Method of Production of the Material – – Fourth U.S. Patent Directed to…
